Technology | June 16, 2011

Cordis Discontinues Cypher Stent, Halts Development of Nevo Stent

June 16, 2011 — Johnson & Johnson subsidiary Cordis International announced Wednesday that it will cease production of the Cypher sirolimus-eluting stent, the first drug-eluting stent (DES) to secure U.S. Food and Drug Administration (FDA) approval, by the end of 2011. The company will also halt production of the Cypher Select Plus as well as development of the Nevo sirolimus DES.

"Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market," said Seth Fischer, company group chair and worldwide chairman, Cordis Corp.

Cordis cited evolving market dynamics as the primary reason for the decision. These dynamics in the DES market include changes in demand, pricing, reimbursement and regulatory requirements for new technologies. The company was the first to introduce a drug-eluting stent, the Cypher, and was the market leader for several years. However, competition from newer generation drug-eluting stents introduced by Boston Scientific, Abbott and Medtronic knocked Cordis out of the top position several years ago and the company has not introduced new DES to reclaim market share.

The company was developing the Nevo stent with an innovative drug polymer loaded into holes in the stent struts in an effort to limit the polymer contact with the vessel wall to help prevent neointimal hyperplasia. Recently, bioresorbable polymers and entirely bioresorbable stents have taken center stage in DES development and appear likely to take over the DES market in the coming years. This change in market direction may have played a role in Cordis' decision to exit the stent market.

The company also claims unlicensed competition from products that infringe Cordis patents, both owned and licensed, has eroded Cypher stent pricing, sales and market share, and has dampened the prospects for Nevo stent commercialization.

The company is scheduled to close plants in Cashel, Ireland where Nevo was to be produced, as well as their Cypher manufacturing plant in San German, Puerto Rico. The company will also consolidate its research and development project teams in Fremont, Calif. In total, the company esimates 900-1,000 positions will be cut.

Cordis will continue its commitment to cardiovascular care and shift focus to expanding its range of vascular solutions for endovascular and cardiology procedures. The company will continue to focus on cardiovascular care through its Biosense Webster and Cordis businesses.

Biosense Webster will continue to build and expand on its global leadership position in the $2.5 billion electrophysiology (EP) market, as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. As the leader in EP navigation systems and ablation therapy, Biosense Webster has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions and a robust product pipeline.

Cordis will expand its portfolio of vascular solutions for endovascular and cardiology procedures, a $12 billion market. The business will focus on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the Incraft stent-graft system, the company's new investigational device for treating abdominal aortic aneurysm (AAA). The company also recently received FDA approval for the Exoseal vascular closure device.

For more information: www.jnj.com

Related Content

Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Overlay Init